CURRICULUM VITAE

PERSONAL DATA

Name & I.D. No.: Yaron Rudman, MD **ID No**.: 032586786

Faculty/Dept: Gray Faculty of Medical & Health Sciences, Tel Aviv University, Israel/Internal Medicine

Hospital/Dept: Institute of Endocrinology & Metabolism
Rabin Medical Center – Beilinson Hospital, Petach Tikva 4941492, Israel

Home Address: 10 David Yellin St., Tel Aviv, Israel

Email: rudman.yaron@gmail.com

Mobile Phone: +972-52-4799047

Date/Place of Birth: April 24, 1986/Israel

A. EDUCATION
PERIODS OF STUDY

University / Institute: Hebrew University of Jerusalem, Jerusalem, Israel
Subject: Medicine
Period: 2009-2016
Degree: **MD**
Date Awarded: 31.10.2016
Title of Doctoral Dissert.: In-vitro inhibition of microRNA molecules in papillary thyroid cancer cells and its effect on proliferation
Supervised by: Prof. Haggi Mazeh

B1. ACADEMIC EXPERIENCE & NOMINATIONS

Period	Country	Name of Institution Department	Rank/Function
2020	Tel Aviv, Israel	Gray Faculty of Medical & Health Sciences, Tel Aviv University	Tutor to 4th year medical students [Internal Medicine]
2023	Tel Aviv, Israel	Gray Faculty of Medical & Health Sciences, Tel Aviv University	Bedside teaching to Internal medicine 4th year clerkship (01313102)
2024	Tel Aviv, Israel	Gray Faculty of Medical & Health Sciences, Tel Aviv University	Lecturer to 2nd year TAUNY program medical students [Diabetes case-based learning]
2024	Tel Aviv, Israel	Gray Faculty of Medical & Health Sciences, Tel Aviv University	Bedside teaching to Internal medicine 6th year clerkship (01114115)
2024-2026	Tel Aviv, Israel	CME studies, Gray Faculty of Medical & Health Sciences, Tel Aviv University	Lecturer to Internal medicine Interns

B2. PROFESSIONAL EXPERIENCE

Period	Country	Name of Institution Department	Rank/Function
2015-2016	Petach Tikva, Israel	Rabin Medical Center – Beilinson Hospital	Medical Internship
2017-2021	Petach Tikva, Israel	Department of Internal Medicine E, Rabin Medical Center – Beilinson Hospital	Resident
2021-2022	Petach Tikva, Israel	Internal Medicine Counseling Clinic, Rabin Medical Center – Beilinson Hospital	Senior Physician
2022-2024	Petach Tikva, Israel	Institute of Endocrinology & Metabolism, Rabin Medical Center – Beilinson Hospital	Resident
2024-2025	Petach Tikva, Israel	Institute of Endocrinology & Metabolism, Rabin Medical Center – Beilinson Hospital	Senior Physician
2025-2026	Toronto, ON, Canada	Endocrine Oncology Clinic, Toronto General Hospital/University Health Netwotk – University of Toronto	Clinical Fellow

B3. ACTIVE PARTICIPATION IN SCIENTIFIC MEETINGS

Date	Country	Subject & Name of Conference	Role
2017	Eilat, Israel	Israel Society of Internal Medicine Convention	Oral presentation [Best Presentation]
2020	UK [Virtual]	e-ECE 2020: 22nd European Congress of Endocrinology	Poster
2021	Israel [Virtual]	49th Annual Meeting of The Israeli Endocrine Society	Oral presentation
2022	Jerusalem, Israel	50th Annual Meeting of The Israeli Endocrine Society	Oral presentation
2022	Milan, Italy	ECE 2020: 24th European Congress of Endocrinology	Poster
2022	Lyon, France	20th European NeuroEndocrine Association (ENEA) Congress	Poster
2023	Tel Aviv, Israel	51st Annual Meeting of The Israeli Endocrine Society	Oral presentation
2023	Chicago, Illinois, USA	ENDO 2023: The Annual Meeting of The Endocrine Society	Poster

2023	Munich, Germany	The 8th European NeuroEndocrine Association (ENEA) Workshop, Precision Pituitary Medicine	Oral presentation
2024	Tel Aviv, Israel	52nd Annual Meeting of The Israeli Endocrine Society	Oral presentation
2024	Annecy, France	12th European Multidisciplinary Course of Pituitary Tumours (EuroPit 2024)	Oral presentation
2025	Tel Aviv, Israel	53rd Annual Meeting of The Israeli Endocrine Society	Oral presentation

B4. MEMBERSHIP IN PROFESSIONAL SOCIETIES

Years (period)	Name of Organization
2017-2020	Israel Society of Internal Medicine
Since 2020	Israel Endocrine Society
Since 2020	European Society of Endocrinology
Since 2022	European NeuroEndrocrine Assocition (ENEA)
Since 2023	Endocrine Society
Since 2023	The Pituitary Society

C. HONORS, AWARDS, PRIZES AND PATENTS

Apr 2015	Infectious disease elective and scholarship in Mekelle, Ethiopia awarded to Exceptional Medical Students Faculty of Medicine, Hebrew University of Jerusalem, Israel
Jul 2017	Outstanding Research Scholarship and Award Israel Society of Internal Medicine Convention, Eilat, Israel
Jul 2017	Israel Society of Internal Medicine and Bayer Research Grant Award for research project entitled: “Treating hospitalized patients with Heparin-induced thrombocytopenia with Rivaroxaban: a prospective cohort study”
Jun 2023	The Israeli Endocrine Society Travel Grant Award for research abstract entitled: “Hemoglobin Decline as a Signal for Hyperprolactinemia Onset Prior to Prolactinoma Diagnosis in Hypogonadal Men”
June 2025	The Israeli Endocrine Society Award for Best Poster Presentation for research abstract entitled: " Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study"
June 2025	Awarded the Davidoff Cancer Center Scholarship for Advanced Fellowship Training in Endocrine Oncology: neuroendocrine tumors and pituitary diseases.

SCIENTIFIC PUBLICATIONS

A. BOOKS AND MONOGRAPHS

B. TEXTBOOKS

B.1. ORIGINAL ARTICLES

B.1. Articles Published

1. Weiss A, **Rudman Y**, Beloosesky Y, Akirov A, Shochat T, Grossman A*.
High blood pressure variability predicts 30-day mortality but not 1-year mortality in hospitalized elderly patients.
Blood Press. 2017 Oct;26(5):259-263.
(Peripheral Vascular Disease IF 2.107, 41/65, Q3, Times cited: 1)

2. Ayalon-Dangur I, **Rudman Y**, Shochat T, Shiber S, Grossman A*.
Elevated blood pressure during emergency departments visit is associated with increased rate of hospitalization for heart failure: A retrospective cohort study.
J Clin Hypertens (Greenwich). 2018 Jan;20(1):98-103.
(Peripheral Vascular Disease IF 2.444, 35/65, Q3, Times cited: 7)

3. Shimon I*, **Rudman Y**, Manisterski Y, Gorshtein A, Masri H, Duskin-Bitan H.
True hyperprolactinemia in men without visible pituitary adenoma.
Endocrine. 2021 Jun;72(3):809-813.
(Endocrinology & Metabolism IF 3.925, 79/146, Q3, Times cited: 1)

4. **Rudman Y**, Duskin-Bitan H, Manisterski Y, Pertzov B, Akirov A, Masri-Iraqi H, Shimon I*.
Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter?
Clin Endocrinol (Oxf). 2021 Oct;95(4):606-617.
(Endocrinology & Metabolism IF 3.523, 93/146, Q3, Times cited: 3)

5. **Rudman Y**, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I*.
Predicting hypogonadotropic hypogonadism persistence in male macroprolactinoma.
Pituitary. 2022 Dec;25(6):882-890.
(Endocrinology & Metabolism IF 3.599, 90/146, Q3, Times cited: 2)

6. Akirov A*, Dery L, Fleseriu M, **Rudman Y**, Shimon I, Manisterski Y, Aviran-Barak N, Nadler V, Alboim S, Shochat T, Tsvetov G, Hirsch D.
Cushing's syndrome in women: age-related differences in etiology and clinical picture.
Pituitary. 2023 Feb;26(1):144-151.
(Endocrinology & Metabolism IF 3.599, 90/146, Q3, Times cited: 0)

7. Akirov A[#]*, **Rudman Y[#]**.
[[#]Equal contribution].
The role of aromatase inhibitors in male prolactinoma.
J Clin Med. 2023;12:1437.
(Medicine, General & Internal IF 4.964, 55/172, Q2, Times cited: 2)

8. **Rudman Y**, Duskin-Bitan H, Richter I, Tsvetov G, Masri-Iraqi H, Akirov A, Shimon I*.
Hemoglobin decline as a signal for hyperprolactinemia onset prior to prolactinoma diagnosis in hypogonadal men.
Andrology. Mar 2023.
(Andrology IF 4.456, 2/8, Q1, Times cited: 0)

9. Masri-Iraqi H[#], **Rudman Y[#]**, Friedrich Dubinchik C, Dotan I, Diker-Cohen T, Sasson L, Shochat T, Shimon I, Robenshtok E, Akirov A*.
[#Equal contribution].
The Association Between Hypothyroidism Treatment and Mortality in Patients Hospitalized in Surgical Wards.
Endocr Res. 2023;48(2-3):68-76.
(Endocrinology & Metabolism IF 1.5, 153/186, Q4, Times cited: 1)

10. Dotan I, **Rudman Y**, Turjeman A, Akirov A, Steinmetz T, Calvarysky B, Diker Cohen T.
Glucagon-like Peptide 1 Receptor Agonists and Cardiovascular Outcomes in Solid Organ Transplant Recipients With Diabetes Mellitus.
Transplantation. 2024 Jul 1;108(7):e121-e128.
(Tranplantation IF 5.5, 3/31, Q1, Times cited: 4)

11. Ayalon-Dangur I, **Rudman Y**, Tsvetov G, Slutzky-Shraga I, Akirov A, Shimon I, Hirsch D, Gorshtein A.
Long-term effectiveness of zoledronic acid in patients with Paget's disease of bone - a retrospective cohort study.
Endocrine. 2024 Aug;85(2):873-882.
(Endocrinology & Metabolism IF 3, 88/186, Q2, Times cited: 1)

12. Dery L, Stern J, Shimon I, **Rudman Y**, Kushnir S, Shochat T, Fleseriu M, Akirov A*.
Impact of etiology, sex, diabetes mellitus and remission status on erythrocytic profile in patients with cushing's syndrome: a large population database study.
Pituitary. 2024 Aug;27(4):389-402.
(Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 2)

13. **Rudman Y**, Fleseriu M, Dery L, Masri-Iraqi H, Sasson L, Shochat T, Kushnir S, Shimon I, Akirov A*.
Endogenous Cushing's syndrome and cancer risk.
Eur J Endocrinol. 2024 Aug 5;191(2):223-231.
(Endocrinology & Metabolism IF 5.3, 27/186, Q1, Times cited: 13)

14. **Rudman Y**, Duskin-Bitan H, Masri-Iraqi H, Akirov A, Shimon I*.
Visual morbidity in macroprolactinoma: A retrospective cohort study.
Clin Endocrinol (Oxf). 2024 Dec;101(6):648-658.
(Endocrinology & Metabolism IF 3, 88/186, Q2, Times cited: 4)

15. Sharon Y, Shochat T, **Rudman Y**, Kushnir S, Zahavi A, Shimon I, Fleseriu M, Akirov A*.
Higher risk and earlier onset glaucoma in Cushing's syndrome.
Acta Ophthalmol. 2024 Nov 5. (Online ahead of print).
(Ophthalmology IF 3, 18/95, Q1, Times cited: 1)

16. **Rudman Y**[#], Michaelis M[#], Shimon I, Dotan I, Shochat T, Kushnir S, Fleseriu M, Akirov A*.
[#Equal contribution].
Can we predict the risk of venous thromboembolism in patients with Cushing's syndrome: a nationwide cohort analysis.
Pituitary. 2024 Dec 27;28(1):10.
(Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 7)

17. Dery L, Shimon I, **Rudman Y**, Iraqi HM, Kushnir S, Shochat T, Cooper O, Akirov A*.
Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia.
J Endocrinol Invest. 2025 Mar;48(3):691-699.
(Endocrinology & Metabolism IF 3.9, 51/186, Q2, Times cited: 1)

18. Sharon Y, Shochat T, **Rudman Y**, Kushnir S, Zahavi A, Shimon I, Fleseriu M, Akirov A*.
Cushing's syndrome related to higher rates and earlier onset of cataract: A nationwide retrospective cohort study.
Graefes Arch Clin Exp Ophthalmol. 2025 Jan 23. (Online ahead of print).
(Ophthalmology IF 2.4, 32/95, Q2, Times cited: 0)

19. Masri-Iraqi H, **Rudman Y**, Shochat T, Kushnir S, Shimon I, Fleseriu M, Akirov A*.
Leukocytosis in Cushing's syndrome persists post-surgical remission and could predict a lower remission prognosis in patients with Cushing's disease.
J Endocrinol Invest. 2025 Jan 28. (Online ahead of print).
(Endocrinology & Metabolism IF 3.9, 51/186, Q2, Times cited: 0)

20. Akirov A*, **Rudman Y**, Sharon Y, Shimon I, Kushnir S, Diker-Cohen T.
Ischemic stroke risk in patients with dopamine agonist-treated hyperprolactinemia.
J Neuroendocrinol. 2025 Feb 9:e13494. (Online ahead of print).
(Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 0)

21. Drozdinsky G, Halperin E, Kushnir S, **Rudman Y**, Gafter-Gvili A*.
The utility of inpatient work-up of incidental anemia during hospitalization for an acute medical condition: a retrospective cohort study.
Am J Med Sci. 2025 Feb 14:S0002-9629(25)00924-3. (Online ahead of print).
(Medicine, General & Internal IF 2.3, 88/329, Q2, Times cited: 0)

22. Diker Cohen T*, **Rudman Y**, Turjeman A, Akirov A, Steinmetz T, Calvarysky B, Dotan I.
Glucagon-like peptide 1 receptor agonists and renal outcomes in kidney transplant recipients with diabetes mellitus.
Diabetes Metab. 2025 Feb 15;51(3):101624. (Online ahead of print).
(Endocrinology & Metabolism IF 4.6, 36/186, Q1, Times cited: 7)

23. **Rudman Y**, Fleseriu M, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I, Akirov A*.
Impact of Remission Status in Endogenous Cushing's Syndrome on Cancer Incidence.
Eur J Endocrinol. 2025 Feb 25.
(Endocrinology & Metabolism IF 5.3, 27/186, Q1, Times cited: 2)

24. **Rudman Y**, Simon N, Shimon R, Drozdinsky G, Markus E, Duskin-Bitan H, Masri-Iraqi H, Tsvetov G, Akirov A, Shimon I*.
Response to cabergoline treatment, gonadal axis recovery, and outcomes of drug withdrawal, in men with microprolactinoma: a retrospective cohort study.
Endocrine. 2025 Mar 3.
(Endocrinology & Metabolism IF 3.0, 88/186, Q2, Times cited: 7)

25. Duskin-Bitan H, Perez A, Netzer D, Cohen AD, Comaneshter D, Beckenstein T, Yaron S, Adnan Z, **Rudman Y**, Iraqi HM, Shimon I*.
Increased cancer risk in a cohort of patients with acromegaly in Israel.
Endocr Relat Cancer. 2025 Mar 24.
(Endocrinology & Metabolism IF 4.6, 43/186, Q1, Times cited: 4)

26. Akirov A, Fleseriu M, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I, **Rudman Y***.
Mortality in Cushing's syndrome: declining over 2 decades but remaining higher than the general population.
Eur J Endocrinol. 2025 Mar 27.
(Endocrinology & Metabolism IF 5.3, 27/186, Q1, Times cited: 9)

27. **Rudman Y**, Drozdinsky G, Masri-Iraqi H, Shochat T, Kushnir S, Shimon I, Fleseriu M, Akirov A*.
Predictors of cancer in patients with endogenous Cushing's syndrome.
Endocr Relat Cancer. 2025 Jun 24.
(Endocrinology & Metabolism IF 4.6, 43/186, Q1, Times cited: 1)

28. Sasson L, Dery L, Stern J, Shimon I, **Rudman Y**, Dotan I, Kushnir S, Shochat T, Fleseriu M, Akirov A*.
Weight gain reversibility and BMI following treatment for Cushing's syndrome: long-term outcomes and potential predictors.
Pituitary. 2025 Jun 26.
(Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 3)

29. Markus E, **Rudman Y**, Koren S, Shimon I*.
High prevalence of adrenal imaging abnormalities in Cushing's disease.
Endocrine. 2025 Dec 4.
(Endocrinology & Metabolism IF 3, 88/186, Q2, Times cited: 0)

30. Ayalon-Dangur I, Shimon I, Shochat T, Kushnir S, **Rudman Y**, Dotan I, Agrawal N, Fleseriu M, Akirov A*.
Mortality in patients with dopamine agonist-treated hyperprolactinemia: a large matched-cohort study.
Pituitary. 2025 Oct 22.
(Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 1)

31. Lerman A, Shtraichman O, **Rudman Y**, Kramer MR, Dotan I, Tsvetov G, Diker Cohen T*.
Bone Health in Young Lung Transplant Recipients: A Retrospective Study.
Respiration. 2026 Jan 12.
(Respiratory System IF 3.8, 25/108, Q1, Times cited: 0)

32. Agrawal N, Shah SN, Kushnir S, Shochat T, **Rudman Y**, Fleseriu M, Akirov A*.
Age and hematologic parameters can predict prolonged glucocorticoid replacement after remission of cushing disease and adrenal Cushing's syndrome: A nationwide cohort study.
Pituitary. 2026 Mar 25.
(Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 0)

B.1.1. Articles Submitted

B.2. CASE REPORTS (in peer reviewed journals only)

B.2. Case Reports published

B.2. Case Reports Accepted

B.2. Case Reports Submitted

B.3. REVIEW ARTICLES

B.3. Review Articles Published

1. Akirov A, **Rudman Y**, Fleseriu M*.
   Hypopituitarism and bone disease: pathophysiology, diagnosis and treatment outcomes.
   Pituitary. 2024 Dec;27(6):778-788.
   (Endocrinology & Metabolism IF 3.3, 77/186, Q2, Times cited: 12)

2. **Rudman Y**, Shimon I*.
   Hypogonadism in men with prolactinoma: Diagnosis, treatment, and management of persistent hypogonadism.
   Vitamins and Hormones. 2024.
   (Endocrinology & Metabolism IF 2.5, 80/186, Q2, Times cited: 2)

3. **Rudman Y**, Shimon I*.
   Efficacy and long-term outcomes of dopamine agonist treatment in prolactinomas.
   Best Pract Res Clin Endocrinol Metab. 2026 Feb 17.
   (Endocrinology & Metabolism IF 6.1, 77/186, Q1, Times cited: 0)

B.3. Review Articles Submitted

C. CHAPTERS IN BOOKS

D.1. INVITED PAPERS IN SCIENTIFIC MEETINGS

D.2. PAPERS PRESENTED AT SCIENTIFIC MEETINGS PUBLISHED AS PROCEEDINGS and D.3. ABSTRACTS

E. ITEMS IN ENCYCLOPEDIAS

F. BOOKS EDITED

G. OTHER PUBLICATIONS (Encyclopedias; Reports; Letter to Editors)